Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-024650
Filing Date
2025-05-12
Accepted
2025-05-12 16:01:52
Documents
63
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sgmo-20250331.htm   iXBRL 10-Q 806727
2 EX-31.1 sgmo-20250331xex311.htm EX-31.1 10018
3 EX-31.2 sgmo-20250331xex312.htm EX-31.2 10133
4 EX-32.1 sgmo-20250331xex321.htm EX-32.1 7128
  Complete submission text file 0001628280-25-024650.txt   5195150

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20250331.xsd EX-101.SCH 41742
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT sgmo-20250331_cal.xml EX-101.CAL 54656
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sgmo-20250331_def.xml EX-101.DEF 202790
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20250331_lab.xml EX-101.LAB 526287
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20250331_pre.xml EX-101.PRE 378914
66 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20250331_htm.xml XML 559370
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30171 | Film No.: 25934600
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)